Butterfly Network, Inc. to Report First Quarter 2023 Financial Results on May 11, 2023

BURLINGTON, Mass. & NEW YORK–(BUSINESS WIRE)–Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with handheld, whole-body ultrasound, announced that it will report first quarter 2023 financial results and provide a business update on May 11, 2023, before the market opens.

Joseph DeVivo, President, Chief Executive Officer, and Chairman of the Board; Heather Getz, Executive Vice President and Chief Financial Officer; and Darius Shahida, Chief Strategy Officer, will host a conference call and webcast at 8:30 am ET on May 11, 2023 to discuss first quarter 2023 financial results and operational progress.

The conference call will be broadcast live in listen-only mode via a webcast on Butterfly’s Investor Relations website at Events & Presentations.

Individuals interested in listening to the conference call on your telephone may do so by dialing approximately ten minutes prior to start time:

United States: 1 (833) 470 1428

Global Dial-In Numbers: https://www.netroadshow.com/events/global-numbers?confId=49034
Access Code: 669966

After the live webcast, the call will be archived on Butterfly’s Investor Relations page.

In addition, a telephone replay of the call will be available until May 25, 2023, by dialing:

United States: 1 (866) 813 9403

Canada: 1 (226) 828 7578

All other locations: +44 204 525 0658

Access Code: 606818

About Butterfly Network, Inc.

Founded by Dr. Jonathan Rothberg in 2011 and listed on the New York Stock Exchange through a business combination with Longview Acquisition Corp., Butterfly created the world’s first handheld, single probe whole-body ultrasound system using semiconductor technology, the Butterfly iQ+. Butterfly’s mission is to democratize medical imaging and contribute to the aspiration of global health equity, making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Through its proprietary Ultrasound-on-Chip™ technology, Butterfly is paving the way for earlier detection and remote management of health conditions around the world. The Butterfly iQ+ can be purchased today by trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, North America and South America; to learn more about available countries, visit: butterflynetwork.com/choose-your-country. Butterfly iQ+ is a prescription device intended for qualified healthcare professionals only. For more information, visit www.butterflynetwork.com.

Contacts

Investors

Heather Getz

[email protected]

Media

Liz Learned

[email protected]

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.